Abstract:A series of new 2,4‐dichloro‐6‐methylpyrimidine derivatives were designed and synthesized as potential epidermal growth factor receptor (EGFR)T790M/L858R inhibitors for the treatment of non‐small cell lung cancer (NSCLC), among which L‐18 was the most promising antitumor compound. Many patients with non‐small cell lung cancer (NSCLC) initially benefit from epidermal growth factor receptor (EGFR) targeted therapy. Unfortunately, varying degrees of resistance or side effects eventually develop. Overcoming and preventing the resistance and side effects of EGFR inhibitors has become a hot topic of research today. Based on the previous studies on AZD‐9291, we designed and synthesized two series of 2,4‐dichloro‐6‐methylpyrimidine derivatives, 19 compounds in total, as potential inhibitors of the EGFR kinase. The most promising compound, L‐18, showed better inhibitory activity (81.9%) and selectivity against EGFRT790M/L858R kinase. In addition, L‐18 showed strong antiproliferative activity against H1975 cells with an IC50 value of 0.65 ± 0.06 μM and no toxicity to normal cells (LO‐2). L‐18 was able to dose‐dependently induce the apoptosis of H1975 cells and produced a cell‐cycle‐blocking effect, and it can also dose‐dependently inhibit the migration and invasion of H1975 cells. L‐18 also showed in vivo anticancer efficacy in H1975 cells xenograft mice. We also performed a series of in vivo and in vitro toxicological evaluations of compound L‐18, which did not cause obvious injury in mice during administration. These results suggest that L‐18 may be a promising drug candidate that warrants further investigation.

Design, Synthesis, and Biological Evaluation of Pyrimido[4,5- d]pyrimidine-2,4(1 H,3 H)-diones as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation.

Structure-Guided Design of C4-alkyl-1,4-dihydro-2 H -pyrimido[4,5- d ][1,3]oxazin-2-ones as Potent and Mutant-Selective Epidermal Growth Factor Receptor (EGFR) L858R/T790M Inhibitors

Discovery and Structural Optimization of N5-Substituted 6,7-Dioxo-6,7-dihydropteridines As Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors Against L858R/T790M Resistance Mutation.

Design, Synthesis, Anti-Tumor Activity, and Molecular Modeling of Quinazoline and Pyrido[2,3-D]Pyrimidine Derivatives Targeting Epidermal Growth Factor Receptor

Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine 790 → methionine 790 mutant

Design, Synthesis and Biological Evaluation of Novel 2,4-Diaryl Pyrimidine Derivatives As Selective EGFRL858R/T790M Inhibitors.

Discovery of 5-(Methylthio)pyrimidine Derivatives As L858R/T790M Mutant Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors.

Design, synthesis, and biological evaluation of 2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidinyl derivatives as new irreversible epidermal growth factor receptor inhibitors with improved pharmacokinetic properties.

Discovery of 1-{(3R,4R)-3-[5-Chloro-2-(1-methyl-1H-pyrazol-4-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxymethyl]-4-methoxy-pyrrolidin-1-yl}propenone (PF-06459988), A Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants.

Discovery of N-((3r,4r)-4-Fluoro-1-(6-((3-Methoxy-1-Methyl-1h-Pyrazol-4-Yl)Amino)-9-M Ethyl-9h-Purin-2-Yl)Pyrrolidine-3-Yl)Acrylamide (Pf-06747775) Through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic Egfr Mutants with Selectivity over Wild-Type Egfr

Design, synthesis and biological evaluation of aminopyrimidine derivatives bearing a 4,5,6,7-tetrahydrothieno [3,2-c]pyridine as potent EGFR inhibitors

Discovery of Pteridin-7(8H)-one-Based Irreversible Inhibitors Targeting the Epidermal Growth Factor Receptor (EGFR) Kinase T790M/L858R Mutant

Design, synthesis and biological evaluation of potent EGFR kinase inhibitors against 19D/T790M/C797S mutation

Design, synthesis and biological evaluation of new molecules inhibiting epidermal growth factor receptor threonine790 → methionine 790 mutant

Design, Synthesis and Biological Evaluation of the Quinazoline Derivatives As L858R/T790M/C797S Triple Mutant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.

Design, synthesis and antitumor activity of 4-arylamine substituted pyrimidine derivatives as noncovalent EGFR inhibitors overcoming C797S mutation

Rational design and synthesis of 2,4‐dichloro‐6‐methyl pyrimidine derivatives as potential selective EGFRT790M/L858R inhibitors for the treatment of non‐small cell lung cancer

Design, synthesis, and biological evaluation of 2-arylamino-4-(piperidin-4-yloxy)pyrimidines as potent EGFRT790M/L858R inhibitors to treat non-small cell lung cancer

Design, synthesis, and biological evaluation of diphenyl ether substituted quinazolin-4-amine derivatives as potent EGFRL858R/T790M/C797S inhibitors

Design, synthesis and antitumor activity of novel thiophene-pyrimidine derivatives as EGFR inhibitors overcoming T790M and L858R/T790M mutations

Novel Hydrazone Moiety-Bearing Aminopyrimidines As Selective Inhibitors of Epidermal Growth Factor Receptor T790M Mutant